Valion Bio stockholders approve reverse split authority and equity plan increase
At a November 12, 2026 special meeting, Valion Bio shareholders backed a board option for a 1-for-2 to 1-for-12 reverse stock split and added 272,000 shares to its incentive plan.
Valion Bio, Inc. disclosed in an 8-K that it held a special meeting of stockholders in a virtual format on November 12, 20261. As of the October 15, 2026 record date, 2,155,637 shares of common stock were issued, outstanding and entitled to vote1. At the meeting, 1,125,685 shares, or about 52.22% of shares entitled to vote, were represented in person or by proxy, meeting the quorum requirement1. The company noted that holders of its Series A, Series B and Series C Non-Voting Convertible Preferred Stock could not vote those shares on the matters before the meeting1.
Under Proposal 1, shareholders gave the board discretionary authority to amend the company's certificate of incorporation to carry out a reverse stock split at a ratio between 1-for-2 and 1-for-12, with the board free to choose the exact ratio within twelve months of the vote and without needing further shareholder sign-off1. The vote tally was 681,523 shares for and 444,153 against, with 9 abstentions and no broker non-votes1.
Under Proposal 2, shareholders approved increasing the shares available under the company's 2021 Equity Incentive Plan by 272,000 shares1, with results of 466,174 votes for, 131,057 against, 27 abstentions and 528,427 broker non-votes1. The 8-K states that the plan amendment took effect immediately upon stockholder approval1, and that no other terms of the 2021 Plan changed besides the share reserve and related conforming edits1.
Proposal 3, authorizing the board to adjourn the meeting if needed to gather more proxy votes for the other proposals1, also passed, with 686,478 votes for, 438,311 against and 896 abstentions1. The filing was signed by Dean Zikria, Valion Bio's interim chief executive officer, on November 16, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.